Optimization of 131I activity value required for thyroid remnants and metastatic lesions ablation in children with differentiated thyroid cancer

被引:0
|
作者
Kozak, OV [1 ]
Shishkina, VV [1 ]
Korchinskaya, OL [1 ]
Sagan, DL [1 ]
Dzhuza, DA [1 ]
Trocevskiy, VV [1 ]
机构
[1] Ukraine Acad Med Sci, Inst Oncol, UA-03022 Kiev, Ukraine
关键词
thyroid cancer in children; I-131;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
66 children with differentiated thyroid cancer have been treated with I'll after thyroidectomy. Activities administered amounted from 370 to 5600 MBq. Patients were divided into three groups according to scintigraphy data: Group 1-with thyroid remnants only (25 patients), Group 2-with metastatic lesions in lymph nodes (15 patients), Group 3-with metastatic lesions in lungs (26 patients). The aim of the study was to evaluate parameters of radioiodine accumulation and excretion in remnants during radioiodine treatment in children after thyroidectomy, to determine the influence of I'll activity value on the result of the first course of radioiodine treatment. The fraction (f) of patients with thyroid remnants ablation after first course of the treatment within each specified activity range has been calculated and plotted against each interval of I-131 activity. In Group 3 number of courses required for total ablation of thyroid tissue was evaluated as a function of activities administered. In Group 1 f has a constant value (about 0.55) within the range of 1000-2500 MBq followed by the abrupt increase (up to 1) at 2500 MBq remaining at this plateau value with further increase of activity. In Group 3 number of courses of radioiodine treatment largely depends first activity value, namely the greater is first activity value the less is number of courses required for total ablation of remnants and metastatic lesions. The activity 2500 MBq could be considered as an optimal value for thyroid remnants ablation after first course of radioiodine treatment in children without metastatic lesions accumulating radioiodine, while in groups with metastatic lesions, for minimizing number of courses, first activity should be not less then 4000 MBq.
引用
收藏
页码:221 / 224
页数:4
相关论文
共 50 条
  • [31] Clinical pathway of metabolic therapy with 131I in differentiated thyroid cancer
    Saiz, I. Blanco
    Apinaniz, E. Anda
    Arribas, J. Pineda
    Moreno, F. Caudepon
    Iglesias, A. Fernandez
    Jimenez, M. Huarte
    Munoz, A. I. de Miguel
    Aristorena, M. I. Irigoyen
    Girones, E. Goni
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (03): : 178 - 187
  • [32] Dosimetry clinical application in differentiated thyroid cancer treated with 131I
    Testanera, G.
    Antunovic, L.
    Tosi, G.
    Pusceddu, M.
    Leonardi, L.
    Roffinengo, C.
    Tarullo, G.
    Chiti, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S463 - S463
  • [33] The value of detectable thyroglobulin in patients with differentiated thyroid cancer after initial 131I therapy
    van Dijk, D.
    Plukker, J. T. M.
    van der Horst-Schrivers, A. N. A.
    Jansen, L.
    Brouwers, A. H.
    Muller-Kobold, A.
    Sluiter, W. J.
    Links, T. P.
    CLINICAL ENDOCRINOLOGY, 2011, 74 (01) : 104 - 110
  • [34] Value of 131I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature
    Yan-Li Xue
    Zhong-Ling Qiu
    Hong-Jun Song
    Quan-Yong Luo
    European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40 : 768 - 778
  • [35] Role of 131I in low-risk differentiated thyroid cancer
    Vallejo, J. A.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (01): : 33 - 37
  • [36] Is 740 MBq of iodine 131 (131I) an ablative dose for thyroid remnants, after total thyroidectomy for low risk group patients with differentiated thyroid cancer ?
    Cuif-Job, A.
    Fieffe, S.
    Kere, D.
    Wernert, R.
    Pochart, J.
    Schvartz, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S222 - S223
  • [37] Successful ablation with 131I in patients with differentiated thyroid cancer: can TNM staging system predict it?
    Rodriguez-Gasen, A.
    Vercher-Conejero, J.
    Suils-Ramon, J.
    Mora Salvado, J.
    Benitez Segura, A.
    Bajen Lazaro, M.
    Rubio-Alvarez, L.
    Gamez-Cenzano, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S608 - S608
  • [38] Importance of Postoperative Stimulated Thyroglobulin Level at the Time of 131I Ablation Therapy for Differentiated Thyroid Cancer
    Hasbek, Zekiye
    Turgut, Bulent
    Kilicli, Fatih
    Altuntas, Emine Elif
    Yucel, Birsen
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (06) : 2523 - 2527
  • [39] The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I
    Verburg, F. A.
    Verkooijen, R. B. T.
    Stokkel, M. P. M.
    van Isselt, J. W.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2009, 48 (04): : 138 - 142
  • [40] Contribution Of 131I SPECT/CT To Planar Imaging In Post-Ablation Differentiated Thyroid Cancer
    Quirce Pisano, M.
    Andres-Pacheco, J.
    Jimenez-Bonilla, J.
    Martinez-Rodriguez, I.
    Martinez-Amador, N.
    De Arcocha-Torres, M.
    Sanchez-Salmon, A.
    Cuenca-Vera, O.
    Molina-Mendoza, G.
    Banzo, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S611 - S611